Literature DB >> 18361539

Diagnosis and treatment of giant cell arteritis.

Fabrizio Cantini1, Laura Niccoli, Carlotta Nannini, Michele Bertoni, Carlo Salvarani.   

Abstract

Giant cell arteritis (GCA) is a chronic granulomatous vasculitis of unknown aetiology occurring in the elderly. It affects the cranial branches of the arteries originating from the aortic arch and is usually associated with markedly elevated acute-phase reactants. In 10-15% of cases the extra-cranial branches of the aortic arch are involved. GCA is closely related to polymyalgia rheumatica (PMR), although the relationship between the two disorders is still unclear. New-onset headache, scalp tenderness, jaw claudication, temporal artery abnormalities on physical examination, visual symptoms and associated PMR represent the most typical and frequent features of the disease. Systemic manifestations, including fever, anorexia and weight loss, are observed in 50% of cases. Less frequent manifestations are related to the central or peripheral nervous systems, the respiratory tract and extra-cranial large-vessel involvement. As GCA is characterized by a wide spectrum of clinical manifestations, it is important to recognize the different onset patterns of the disease and related diagnostic steps. The diagnosis is relatively straightforward in the presence of typical cranial manifestations, but it may be challenging in the case of a normal erythrocyte sedimentation rate, occult GCA or in patients with isolated extra-cranial features. Temporal artery biopsy still represents the gold standard for diagnosis, while the role of ultrasonography, high-resolution magnetic resonance imaging and positron emission tomography should be better addressed. Corticosteroids remain the therapy of choice. Data supporting the usefulness of antiplatelet agents and anticoagulants combined with corticosteroids to prevent ischaemic complications as well as the corticosteroid-sparing effect of methotrexate and anti-tumour necrosis factor-alpha drugs are limited and non-conclusive.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18361539     DOI: 10.2165/00002512-200825040-00002

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  112 in total

1.  Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs.

Authors:  P Airò; C M Antonioli; M Vianelli; P Toniati
Journal:  Rheumatology (Oxford)       Date:  2002-03       Impact factor: 7.580

2.  Detection of parvovirus B19 DNA by polymerase chain reaction in giant cell arteritis: a case-control study.

Authors:  Carlo Salvarani; Enrico Farnetti; Bruno Casali; Davide Nicoli; Liu Wenlan; GianLuigi Bajocchi; PierLuigi Macchioni; Giovanni Lo Scocco; Maria Grazia Catanoso; Luigi Boiardi; Fabrizio Cantini
Journal:  Arthritis Rheum       Date:  2002-11

3.  Proximal bursitis in active polymyalgia rheumatica.

Authors:  C Salvarani; F Cantini; I Olivieri; L Barozzi; L Macchioni; L Niccoli; A Padula; M De Matteis; P Pavlica
Journal:  Ann Intern Med       Date:  1997-07-01       Impact factor: 25.391

4.  Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis.

Authors:  J K Rao; N B Allen; T Pincus
Journal:  Ann Intern Med       Date:  1998-09-01       Impact factor: 25.391

5.  Lack of association between infection and onset of polymyalgia rheumatica.

Authors:  J Narváez; M T Clavaguera; J M Nolla-Solé; J Valverde-Garcia; D Roig-Escofet
Journal:  J Rheumatol       Date:  2000-04       Impact factor: 4.666

6.  Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.

Authors:  Michael S Lee; Scott D Smith; Anat Galor; Gary S Hoffman
Journal:  Arthritis Rheum       Date:  2006-10

7.  Long-term corticosteroid treatment in giant cell arteritis.

Authors:  R Andersson; B E Malmvall; B A Bengtsson
Journal:  Acta Med Scand       Date:  1986

8.  Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients.

Authors:  Daniël Blockmans; Liesbet de Ceuninck; Steven Vanderschueren; Daniël Knockaert; Luc Mortelmans; Herman Bobbaers
Journal:  Arthritis Rheum       Date:  2006-02-15

9.  Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA.

Authors:  Michele F Doran; Cynthia S Crowson; W Michael O'Fallon; Gene G Hunder; Sherine E Gabriel
Journal:  J Rheumatol       Date:  2002-08       Impact factor: 4.666

10.  Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis?.

Authors:  Carlo Salvarani; Mauro Silingardi; Angelo Ghirarduzzi; Giovanni Lo Scocco; PierLuigi Macchioni; GianLuigi Bajocchi; Marco Vinceti; Fabrizio Cantini; Ido Iori; Luigi Boiardi
Journal:  Ann Intern Med       Date:  2002-08-20       Impact factor: 25.391

View more
  9 in total

Review 1.  An atypical presentation of giant cell arteritis.

Authors:  Jocelyn Zwicker; Edward J Atkins; Cheemun Lum; Mukul Sharma
Journal:  CMAJ       Date:  2011-02-07       Impact factor: 8.262

Review 2.  Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.

Authors:  Eleni I Kampylafka; Harry Alexopoulos; Marinos C Dalakas; Athanasios G Tzioufas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

3.  Th17 and Th1 T-cell responses in giant cell arteritis.

Authors:  Jiusheng Deng; Brian R Younge; Richard A Olshen; Jörg J Goronzy; Cornelia M Weyand
Journal:  Circulation       Date:  2010-02-08       Impact factor: 29.690

4.  [The role of the response to DNA damage in granulomatous diseases].

Authors:  Lea A R Fabry; Antigoni Triantafyllopoulou
Journal:  Z Rheumatol       Date:  2022-08-25       Impact factor: 1.530

5.  Encephalopathy, visual disturbance and hearing loss-recognizing the symptoms of Susac syndrome.

Authors:  Jan Dörr; Helena Radbruch; Markus Bock; Jens Wuerfel; Anne Brüggemann; Klaus P Wandinger; Daniel Zeise; Caspar F Pfueller; Frauke Zipp; Friedemann Paul
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

Review 6.  [Clinical and serological findings of giant-cell arteritis].

Authors:  P Vaith; K Warnatz
Journal:  Z Rheumatol       Date:  2009-03       Impact factor: 1.372

7.  Scalp necrosis as a late sign of giant-cell arteritis.

Authors:  Mohammad Alimohammadi; Ann Knight
Journal:  Case Reports Immunol       Date:  2013-01-09

8.  Serpin treatment suppresses inflammatory vascular lesions in temporal artery implants (TAI) from patients with giant cell arteritis.

Authors:  Hao Chen; Donghang Zheng; Sriram Ambadapadi; Jennifer Davids; Sally Ryden; Hazem Samy; Mee Bartee; Eric Sobel; Erbin Dai; Liying Liu; Colin Macaulay; Anthony Yachnis; Cornelia Weyand; Robert Thoburn; Alexandra Lucas
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

9.  Horton's disease: still an important medical problem in elderly patients: a review and case report.

Authors:  Krzysztof Gomułka; Joanna Radzik-Zając; Urszula Zaleska-Dorobisz; Bernard Panaszek
Journal:  Postepy Dermatol Alergol       Date:  2017-10-31       Impact factor: 1.837

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.